Abstract
Abstract The mechanism by which breast ductal carcinoma in situ (DCIS) progresses to invasive ductal carcinoma (IDC) is poorly described. Previous studies have revealed that DCIS and IDC share similar genomes and transcriptomes. We hypothesize that one mechanism contributing to the DCIS to IDC conversion involves aberrations in mRNA translation. The Mnk/eIF4E axis has a critical role in promoting the translation of tumor promoting and pro-invasive mRNAs, thus we propose to study whether aberrant activation of this axis promotes the transition of DCIS to IDC. Our model system involved overexpressing constitutively active Mnk1 (caMNK1) in MCF10 variants: (1) MCF10A immortalized mammary epithelial cells and (2) MCFDCIS.com ductal carcinoma in situ cells (termed DCIS cells). Our in vitro results suggest that caMNK1 enables DCIS cells to gain invasive properties. First, overexpression of caMnk1 increased colony formation, larger acinar size in 3D culture, and promoted the migration and invasion of MCF10A and MCFDCIS cells. Second, SEL201, a novel Mnk1/2 inhibitor, can inhibit proliferation, colony formation, 3D acini formation, and the migration and invasion capacity of DCIS-pBABE and -caMNK1 expressing cells. Tumor xenografting in athymic nude mice revealed that caMNK1 facilitates the conversion of DCIS to IDC as the DCIS-caMNK1 expressing tumors progress to IDC, while DCIS-pBABE derived tumors retain DCIS-like structures. Breast tumor samples from patients with DCIS, IDC or mixed DCIS-IDC will also be obtained to examine the levels of phospho-Mnk1 and phospho-eIF4E. Citation Format: Qianyu Guo, Sonia V. del Rincon, Christophe Goncalves, Wilson H. Miller. MNK1 promotes the progression of breast ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC). [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 686.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call